Sanofi

Our brand-new Modulus facilities have been named as one of TIME Magazine 2025 Best Inventions in Medical & Healthcare! 💜 With the ability to produce multiple vaccines and biologics simultaneously, our first-of-its-kind next-generation sites represent the future of pharmaceutical manufacturing, bringing life-changing treatments to patients faster than ever. We’re building the future of healthcare — and this is only the beginning. Learn more: http://spkl.io/6042AVvsY #TIME2025 #Healthcare #Innovation

Results from a phase 2 study evaluating a new investigational therapy in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) demonstrated potential benefit in a group of cancers with critical unmet needs.     With the results, we remain committed to our ambition of transforming care for people living with rare and difficult-to-treat cancers.     Click here for more information⬇️   https://lnkd.in/emUk_FWY   CC: Orano Med

How do you treat diseases in a place the body is designed to protect? The brain is notoriously hard to reach, but our scientists are finding a way in. By piggybacking on the body’s own transport systems, we are learning to carry therapies across the blood-brain barrier, opening the door to treating a range of rare neurological diseases. In part 2 of our series, Global Head of Rare and Neurological Diseases, Pablo Sardi, explains how we’re using AI and novel delivery platforms to rewrite the script for some of the world’s most challenging conditions. Learn more in our latest article: http://spkl.io/6043AVr47 #RareDisease #Immunoscience #WeNeverSettle

From Paris to Milan, Marseille to Mont-Saint-Michel… Zeus has carried with him the spirit of strength, agility, and determination across the #SanofiTour. 💜✨ Now he returned his birthplace alongside Atelier blam, for a homecoming filled with discovery, science on wheels, and unforgettable encounters. He’s not just coming back as a symbol. He returns as a legend – shaped by every smile, every story, and every shared moment along the way. #WeNeverSettle

At Sanofi, integrity guides every discovery, treatment, and decision we make. That’s why we’ve strengthened our Code of Conduct for 2025 — a compass for how we act and lead with our values: · Aim Higher – power bold leaps in science to transform the practice of medicine. · Act for Patients – never compromise on integrity and safety. · Be Bold – Take thoughtful risks, seize opportunities and think beyond what’s possible. · Lead Together – every voice matters to make healthcare more inclusive. We don’t just follow the Code — we live it. Because when we lead with integrity, the miracles of science become reality. 📘 Explore our updated Code of Conduct: http://spkl.io/6045ATLOd #Integrity #CodeofConduct #Sustainability #Healthcare

Data from our phase 4 head-to-head study in people with chronic rhinosinusitis with nasal polyps (#CRSwNP) and coexisting asthma has been published in The Lancet Respiratory Medicine. These results add to our track record in respiratory disease care. Learn more about the findings: http://spkl.io/6047ATeK3 CC: Regeneron

🌍 Nearly half of the world’s population is living in areas increasingly vulnerable to climate change, facing greater risks to their health. This #ClimateWeek and at #UNGA, we’re proud to reaffirm our commitment to protecting both health and the planet. Through our AIR sustainability strategy, we’re working to address the effects of environmental change on patients, healthcare systems, and future generations. Discover how we’re driving meaningful change: http://spkl.io/6048Ar0L0 #HealthcareForFuture

Only 5% of the 10,000+ known rare diseases have approved treatments. Our R&D strategy is built to tackle this challenge from two fronts: Molecularly Defined Disorders: Targeting the genetic root of disease with enzyme replacement therapies in metabolic diseases, innovations in hemophilia, and exploring next-generation gene therapies. Immune-Driven Mechanisms: Harnessing immunoscience to target harmful inflammation and pursue potentially restorative approaches. In our latest article, Global Head of Rare Diseases Research, Pablo Sardi, shares how we aim to bring transformational therapies to patients that are too often overlooked: http://spkl.io/6041AraQU #RareDisease #Immunoscience #DrugDiscovery #WeNeverSettle

We're boosting our commitment to healthcare innovation with a $625 million investment in Sanofi Ventures, now managing over $1.4 billion. This empowers us to support early-stage biotech and digital health companies in key areas. We believe bold ideas drive the next generation of therapies, and we're investing in the people and science to make them a reality. Read our press release: http://spkl.io/6043ArAfU

The landscape of #MultipleSclerosis (MS) research is rapidly advancing, bringing forward more precise ways to measure disability accumulation and opening new strategies for intervention. By actively researching and sharing new approaches to target the underlying biology of progression, we are working to fundamentally alter the course of disability accumulation – and MS as a whole. Learn more ▶️ http://spkl.io/6041ArFPS